Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-05-09 Declaration of Voting R…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states it is releasing the "NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF MAY 1, 2023" pursuant to French commercial code and AMF regulations. It provides precise figures for total shares outstanding and theoretical/exercisable voting rights. This type of mandatory disclosure regarding the capital structure and voting rights, often released monthly or quarterly, does not fit the definitions for 10-K, ER, IR, or DIV. It is a specific regulatory disclosure concerning share capital and voting power. While it relates to capital structure, it is a periodic disclosure of existing shares rather than a financing event (CAP) or a general share issue announcement (SHA). The closest fit among the provided options for a specific, periodic disclosure related to share structure/voting rights, especially when mandated by a regulator like the AMF, is often categorized under general regulatory filings or specific shareholder/capital updates. Given the options, this is a specific notification about the current state of shares and voting rights. It is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ - which tracks ownership changes crossing thresholds), or a general capital change (SHA). Since it is a specific, mandatory disclosure about the total number of shares and voting rights, it aligns best with a specialized regulatory announcement. However, none of the codes perfectly capture 'Shares and Voting Rights Disclosure'. Comparing the options, it is a specific regulatory update. If it were a change in major shareholding, it would be MRQ. Since it is a statement of the total count, it is a regulatory filing. Given the options, 'RNS' (Regulatory Filings - general fallback) is plausible, but let's re-examine the definitions. It is not a dividend (DIV), not a proxy statement (PSI), and not a transaction in own shares (POS). It is a disclosure of the current capital base for voting purposes. In many contexts, this type of filing is classified as a 'Shares Outstanding' or 'Capital Structure' update. Since 'SHA' is 'Share Issue/Capital Change' (implying an action), and this is a report of the current state, 'RNS' is the safest general regulatory category. However, if we consider the content as a fundamental component of corporate governance reporting related to shareholder rights, it is a highly specific regulatory disclosure. Given the lack of a perfect match, and its nature as a mandatory disclosure to the market authority (AMF), RNS is the most appropriate fallback for a specific regulatory notice not covered elsewhere.
2023-05-09 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a formal announcement dated May 9, 2023, titled "Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er mai 2023" (New number of shares and voting rights of Innate Pharma as of May 1, 2023). It explicitly cites French regulatory articles (Code de Commerce and AMF regulations) regarding the publication of the total number of shares and voting rights. This type of mandatory disclosure, which details changes in the capital structure or voting power, aligns most closely with announcements related to share capital changes or major shareholding notifications. Since it specifically details the total number of shares and voting rights, it is a direct update on the company's share structure. This fits best under 'Share Issue/Capital Change' (SHA) or potentially 'Major Shareholding Notification' (MRQ) if it were crossing a threshold, but since it's a routine total count update mandated by regulation, SHA is the most appropriate fit for capital structure information. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2023-05-09 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-05-03 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-05-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Innate Pharma announcing that several clinical abstracts have been accepted for presentation at the ASCO 2023 annual congress. It provides details on the titles, sessions, and dates of these abstracts, as well as background information on the company's drug candidates and partnerships. It does not contain the actual financial results or the full reports themselves, but rather serves as a corporate announcement regarding upcoming scientific presentations. Therefore, it falls under the category of general regulatory announcements/press releases.
2023-05-03 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release announcing a future conference call and webcast for a Q1 business update. It does not contain the actual financial results or the transcript of the call, but rather provides the logistics for an upcoming event. According to the 'Menu vs Meal' rule, announcements regarding the scheduling of events or the publication of reports are classified as Report Publication Announcements (RPA) or general regulatory filings. Given the nature of the announcement (scheduling an investor event), RPA is the most appropriate category. Q1 2023
2023-05-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.